Antipsychotic Trials in Schizophrenia: The CATIE Project

Description

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

Scott Stroup is Professor of Psychiatry at the University of North Carolina, Chapel Hill, USA. He was co-Principal Investigator of the CATIE Schizophrenia Study. Jeffrey A. Lieberman is Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, Director, New York State Psychiatric Institute and Director, Lieber Center for Schizophrenia Research Psychiatrist-in-Chief at New York Presbyterian Hospital and Columbia University Medical Center, New York, USA.

'... important and timely ...' Doody's 'This book is not just a reprint of all published CATIE papers - it takes us beyond the hype of the first publication by reminding us of the breadth and depth of the trial ... This book will be of major interest to anyone involved in psychopharmacology. However, the richness of the use of social and cognitive end points means that there is a wealth of information for those who have no interest in antipsychotics but are interested in the lives and outcomes of people with schizophrenia.' The British Journal of Psychiatry